MCF7/ExeR-3 Cell Line

A human exemestane-resistant breast cancer model used to study aromatase inhibitor resistance, oestrogen signalling, and hormone-directed therapies.

Contributors

Inventor Institute
Anne Lykkesfeldt Danish Cancer Society, Denmark
SKU: 152557
Product description: MCF7/ExeR-3 is a human breast cancer cell line modelling acquired resistance to exemestane, a third-generation aromatase inhibitor (AI), and was established from parental MCF7/S0.5 cells. Third generation AIs have proven to be effective treatment for oestrogen receptor positive (ER+) breast cancer and as such are recommended as first line endocrine therapy for postmenopausal ER+ breast cancer patients. However, a major problem is the development of resistance against AIs such as exemestane. This cell line can be used to study exemestane resistance mechanisms and to discover novel drug targets to develop next-line therapies.
Alternate name: MCF-7/ExeR-3; ExeR-3
Gender: Female
Conditional: No
Production details: Exemestane-resistant cell lines were established from MCF-7/S0.5 cells grown in medium with 10% NCS and 10-7 M testosterone. A culture of MCF-7/S0.5 cells were treated with 10-7 M exemestane for one week, trypsinised and seeded in serial dilutions in 24-well plates. Single colonies were transferred to new wells and gradually expanded in medium with exemestane. After ~2-3 months, the isolated colonies gave rise to exemestane-resistant cell lines, which could be grown in exemestane-containing medium with a weekly split ratio of ~1:25. This cell line was authenticated in January 2014 by DNA profiling using short tandem repeat loci and found to be matching the genetic profile reported for the MCF-7 cell line.
Cellosaurus ID: CVCL_5A15
Parental cell line: MCF7/S0.5
Disease: Cancer
Cat. #: 152557
Tool sub type: Continuous
Unit size: 1×10^6 cells / vial
Cancer types: Breast cancer
Research Fields: Cancer; Drug development
Organism: Human
Tissue: Breast
Gender: Female
Growth properties: Breast cancer cell line resistant to the aromatase inhibitor exemestane. Estrogen receptor positive.
Cancer Types In Detail: Breast cancer
Primary citation: Hole et al. 2015. Int J Oncol. 46(4):1481-1490. PMID: 25625755.
Format: Frozen
Shipping conditions: Dry ice
Growth medium: Phenol-red-free DMEM/F12 medium supplemented with 10% newborn calf serum, 2.5 mM Glutamax, 6 ng/ ml insulin, 0.1 uM testosterone and 0.1 uM exemestane.
Temperature: 37° C
Atmosphere: Humidified air with 5% CO2
References:

Hole et al. 2015. Breast Cancer Res Treat. 149(3):715-726. PMID: 25667100.

Hole et al. 2015. Int J Oncol. 46(4):1481-90. PMID: 25625755.

Images

View Gallery
MCF7 ExeR-3 Cell Line. Early log phase. Image courtesy of the European Collection of Authenticated Cell Cultures (ECACC)
MCF7 ExeR-3 Cell Line. Mid log phase. Image courtesy of the European Collection of Authenticated Cell Cultures (ECACC), UK.
MCF7 ExeR-3 Cell Line. Late log phase. Image courtesy of the European Collection of Authenticated Cell Cultures (ECACC), UK.

Related Tools for Cell lines

Cat. # Tool Name
152556 MCF7/ExeR-2 Cell Line Key Info View Tool
152555 MCF7/ExeR-1 Cell Line Key Info View Tool
152558 MCF7/ExeR-4 Cell Line Key Info View Tool

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.